Pfizer to raise $10.6B to finance Wyeth buy

27 May 2009

Global drug behemoth Pfizer is to raise $10.6 billion from the only sale of euros in bonds since 2007 and its first-ever sale in pounds sterling,  in order to help finance its $68.0-billion acquisition of fellow  USA-based firm Wyeth (Marketletters passim).

The company is selling 1.85 billion euros ($2.59 billion) in four-year  bonds, 2.0 billion euros in seven-year notes, a further 2.0 billion  euros in 12-year debt and GBP1.5 billion ($2.38 billion) worth due in  2038, according to a source quoted by the Bloomberg news service.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight